Drug Trial Radar · NCT07444762
Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
184
Actual
Start
Apr 21, 2025
Primary completion
Oct 21, 2025
Study completion Oct 21, 2025
Sponsor
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, active-controlled, parallel, phase III clinical trial to evaluate the efficacy and safety of combination therapy of DW5421A/DW5421B versus monotherapy of DW5421A in patients with primary hypercholesterolemia or mixed dyslipidemia.
Conditions
- Primary Hypercholesterolemia
- Mixed Dyslipidemia
Interventions
DW5421ADrug
IP is administered orally once daily at a consistent time each day, with or without food.
DW5421B PlaceboDrug
IP is administered orally once daily at a consistent time each day, with or without food.
DW5421BDrug
IP is administered orally once daily at a consistent time each day, with or without food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- LDL-C change rateTime frame: week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea University Anam Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.